Table 2.

Patient and donor characteristics

CharacteristicsNo. patients
Total patients in study 510  
Median recipient age, y (range) 38 (< 1-62)  
Recipient age distribution, y  
 20 or younger 144  
 21-30 63  
 31-40 85 
 41-50 144  
 51 or older 74  
Sex, donor:recipient  
 M:F 112  
 M:M 190  
 F:M 101 
 F:F 107  
Median time from diagnosis to transplantation, mo (range) 9 (< 1-246) 
Etiology  
 Idiopathic 398  
 Postradiation, chemotherapy, or both 70  
 Postaplastic anemia 26 
 Post-MPD (polycythemia vera, essential thrombocythemia) 3  
 Other disease 4 
 Unknown 9  
Cytogenetics  
 Normal 126 
 Abnormal 238  
 Failure/unknown 146  
Recipient CMV serology  
 Positive 272  
 Negative 234 
 Unknown 4  
HLA-A, -B, -DRB1 matching  
 HLA-A, -B, -DR identical 376  
 Allele potential identical 24 
 Mismatch 110  
Preparative regimen  
 TBI/CY ± other 317  
 BU/CY ± other 128  
 TBI/BU/CY 18 
 Other 47  
GVHD prophylaxis  
 T-cell depletion 121 
 CSA ± other 326  
 Other 63  
Median cell dose (range)  
 Non–T-cell depletion (× 108 nucleated cells/kg) 2.9 (0.07-11.9)  
 T-cell depletion (× 108 nucleated cells/kg) 0.8 (0.02-3.5) 
Donor  
 Median age, y (range) 37 (19-59) 
 No. males 302  
 CMV seropositivity 186 
CharacteristicsNo. patients
Total patients in study 510  
Median recipient age, y (range) 38 (< 1-62)  
Recipient age distribution, y  
 20 or younger 144  
 21-30 63  
 31-40 85 
 41-50 144  
 51 or older 74  
Sex, donor:recipient  
 M:F 112  
 M:M 190  
 F:M 101 
 F:F 107  
Median time from diagnosis to transplantation, mo (range) 9 (< 1-246) 
Etiology  
 Idiopathic 398  
 Postradiation, chemotherapy, or both 70  
 Postaplastic anemia 26 
 Post-MPD (polycythemia vera, essential thrombocythemia) 3  
 Other disease 4 
 Unknown 9  
Cytogenetics  
 Normal 126 
 Abnormal 238  
 Failure/unknown 146  
Recipient CMV serology  
 Positive 272  
 Negative 234 
 Unknown 4  
HLA-A, -B, -DRB1 matching  
 HLA-A, -B, -DR identical 376  
 Allele potential identical 24 
 Mismatch 110  
Preparative regimen  
 TBI/CY ± other 317  
 BU/CY ± other 128  
 TBI/BU/CY 18 
 Other 47  
GVHD prophylaxis  
 T-cell depletion 121 
 CSA ± other 326  
 Other 63  
Median cell dose (range)  
 Non–T-cell depletion (× 108 nucleated cells/kg) 2.9 (0.07-11.9)  
 T-cell depletion (× 108 nucleated cells/kg) 0.8 (0.02-3.5) 
Donor  
 Median age, y (range) 37 (19-59) 
 No. males 302  
 CMV seropositivity 186 
View Large